Clinical Trial Results: Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for pembrolizumab in patients with poor-prognosis carcinoma of unknown primary site.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Carcinoma of Unknown Primary | Phase 2 | Status: COMPLETED | Results posted: 2026-07-02